According to a pharmaceutical expert from the IW, the investments canceled by the pharmaceutical giants Eli Lilly and Boehringer Ingelheim show fundamental challenges for Germany as a location.
“My assessment at this point would be that we are dealing with clear warning shots,” said Jasmina Kirchhoff of the German Press Agency in Mainz. “What we are seeing right now should be taken seriously because these are considerations that many other companies will also be asking themselves.”
The middle of the week was only Boehringer Ingelheim announced that it did not want to invest the 900 million euros planned for the years 2027 to 2030 in German locations. Shortly afterwards, the US company Eli Lilly announced that it would no longer invest 2.5 billion US dollars (around 2.2 billion euros) in its new factory in Alzey in Rhineland-Palatinate, but only half that amount.
Expert: Companies lack planning security
Kirchhoff referred to the planned health care reform in Germany. The Statutory Health Insurance Contribution Stabilization Act is being discussed at a time when general conditions are changing worldwide. The US market is completely repositioning itself, and pressure from Asia is also increasing.
Viewed critically by the Pharmaceutical industry the dynamic manufacturer discounts planned by the federal government as part of the austerity package. “With them it is practically no longer possible to carry out any planning at all because these discounts change every year,” said Kirchhoff. “In addition, one must assume that they will only increase in the future.”
In addition, the law has so far provided for the possibility of discount agreements for innovative medicines, which would undermine the protection of intellectual property. It must also be seen that some countries have already increased their drug budgets in response to US drug policy. “What we’re doing is exactly the opposite.”
Kirchhoff: Conflict of objectives must be addressed
Kirchhoff said that she hopes that German politicians have now understood that there is a serious conflict of objectives between health and economic policy objectives. All ministries involved need to get together and see how this can be combined. It must also be realized that the new direction of US pharmaceutical policy represents a systemic risk for Germany.
What is being done in Germany is particularly important. It is the largest healthcare market in Europe, other European and non-European countries link their prices to German drug prices and the German pharmaceutical industry has an excellent standing. “That means what we do here also sends a signal to other countries.”
/chs/DP/eg
COLOGNE (dpa-AFX)
By the way: Eli Lilly and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leverage products on Eli Lilly
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Eli Lilly
The leverage must be between 2 and 20
Risk warning: Suffer on average 7 out of 10 retail investors Losses when trading with turbo certificates. Turbo certificates are high-risk products and not suitable for long-term investment strategies. Risk warning: Suffer on average 7 out of 10 retail investors Losses when trading with turbo certificates. Turbo certificates are high-risk products and not suitable for long-term investment strategies.
Advertising
Image sources: Jonathan Weiss / Shutterstock.com, Katherine Welles /Shutterstock.com